- Home
- MREO vs CHW Comparison
MREO vs CHW Comparison
Compare MREO & CHW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MREO
- CHW
- Stock Information
- Founded
- MREO 2015
- CHW 2007
- Country
- MREO United Kingdom
- CHW United States
- Employees
- MREO N/A
- CHW N/A
- Industry
- MREO Biotechnology: Pharmaceutical Preparations
- CHW Investment Managers
- Sector
- MREO Health Care
- CHW Finance
- Exchange
- MREO Nasdaq
- CHW Nasdaq
- Market Cap
- MREO 369.2M
- CHW 439.4M
- IPO Year
- MREO N/A
- CHW N/A
- Fundamental
- Price
- MREO $2.26
- CHW $6.41
- Analyst Decision
- MREO Strong Buy
- CHW
- Analyst Count
- MREO 7
- CHW 0
- Target Price
- MREO $7.71
- CHW N/A
- AVG Volume (30 Days)
- MREO 1.2M
- CHW 195.2K
- Earning Date
- MREO 03-26-2025
- CHW 01-01-0001
- Dividend Yield
- MREO N/A
- CHW 9.27%
- EPS Growth
- MREO N/A
- CHW N/A
- EPS
- MREO N/A
- CHW N/A
- Revenue
- MREO N/A
- CHW N/A
- Revenue This Year
- MREO N/A
- CHW N/A
- Revenue Next Year
- MREO $69.09
- CHW N/A
- P/E Ratio
- MREO N/A
- CHW N/A
- Revenue Growth
- MREO N/A
- CHW N/A
- 52 Week Low
- MREO $2.16
- CHW $5.07
- 52 Week High
- MREO $5.02
- CHW $6.54
- Technical
- Relative Strength Index (RSI)
- MREO 33.19
- CHW 33.81
- Support Level
- MREO $2.23
- CHW $6.54
- Resistance Level
- MREO $2.73
- CHW $6.70
- Average True Range (ATR)
- MREO 0.14
- CHW 0.10
- MACD
- MREO -0.01
- CHW -0.01
- Stochastic Oscillator
- MREO 7.89
- CHW 25.39
About MREO Mereo BioPharma Group plc
Mereo BioPharma Group PLC is a United Kingdom (U.K.) based biopharmaceutical company focused on the development of innovative therapeutics for rare diseases. The Company has developed a portfolio of late-stage clinical product candidates, and its two rare disease product candidates are setrusumab for the treatment of osteogenesis imperfecta (OI) and alvelestat primarily for the treatment of severe alpha-1 antitrypsin deficiency-associated lung disease (AATD-LD).
About CHW Calamos Global Dynamic Income Fund
Calamos Global Dynamic Income Fund operates as a closed-end management investment company. The company's investment objective is to generate a high level of current income with the objective of capital appreciation. It dynamically allocates its investment among equities, convertible bonds, fixed-income securities and alternative investments.